

MAY Oral Glucagon-Like-Peptide1 Receptor Agonists Updates

Update 1: Name Change/Dose change for *Semaglutide Tablets*

- Starting May 4: RYBELSUS® will be REBRANDED to OZEMPIC® with new concentrated strengths
- Switching from Rybelsus to Ozempic will require a dose change
 - 3mg Rybelsus = 1.5 mg Ozempic
 - 7 mg Rybelsus = 4 mg Ozempic
 - 14 my Rybelsus = 9 mg Ozempic
 - Ozempic dosing can start the day after the last Rybelsus dose
 - Multi-dosing is not appropriate (cannot take two 1.5mg or a combination of doses to equal a higher dose)

Update 2: A new GLP-1RA oral: *orforglipron*

How it compares to semaglutide oral:

- Orforglipron is a novel non-peptide GLP-1 RA (the new generation), with a smaller molecular structure
 - The KEY advantage to orforglipron vs semaglutide is the flexible administration. It can be taken with or without food once daily
 - GI effects are different - based on clinical trial data:
 - Less Nausea (35% vs 46.6%) and Vomiting (24% vs 30.9%)
 - More Diarrhea (25% vs 17.6%) and Constipation (24% vs 20%)
 - Higher discontinuation rate due to adverse reactions(10% vs 6.9%)
- Note: Clinical trials used a capsule dosage form, so the data reported is for different dosages than the approved tablet formulation.

	Orforglipron	Semaglutide	
Brand Name Product:	Foundayo® Oral Tablets	Rybelsus® → OZEMPIC®	WEGOVY® Oral Tablets
Available since:	2026	2019 --- rebranding 2026	2026
Indication & Efficacy	Weight Management ATTAIN-1 Trial (17.2mg): 11.1% reduction at 72 weeks	Type 2 Diabetes	Weight Management OASIS-4 Trial (25 mg dose): 13.6% reduction at 64 weeks
Other Approved Uses	N/A	CV Risk Reduction	CV Risk Reduction
Dose: once daily	0.8→2.5→5.5→9 →14.5→17.2 mg	Rybelsus: 3 → 7→ 14mg Ozempic: 1.5 → 4 → 9 mg	Wegovy: 1.5→ 4→ 9→ 25 mg
Titration:	Every 30 days	Every 4 weeks	
Administration	Any time of day with or without food	<i>Must be taken on an empty stomach with no more than 4 oz of water, followed by 30 minutes fasting</i>	
Side Effect Profile	Common: Nausea, vomiting, diarrhea, constipation, decreased appetite		
Serious Risks	AVOID in persons with history/risk of thyroid C-cell tumors or MEN2/MTC history Monitor to avoid: gallbladder disease, retinopathy, pancreatitis, sarcopenia		
Drug Interactions:	Delayed gastric emptying, AND Strong CYP3A4 Inhibitors, inducers, Simvastatin	Delays gastric emptying: can impact absorption of oral medications concomitantly administered	
Direct monthly cost	Lilly direct	Novo Care	
	0.8 mg = \$149 2.5mg = \$199 All other doses = \$299	1.5mg = \$149 4mg = \$199 9mg = \$299	New pts: 1.5mg & 4mg: \$149 9mg & 25mg: \$299

References:

- IPD Analytics. *Payer & Provider Insights – New Drug Review: Chronic Weight Management (CWM) / GLP-1 Therapies (Foundayo)*. IPD Analytics; [n.d.]. healthcare@ipdanalytics.com. Accessed May 11, 2026.
- Eli Lilly and Company. (2026). *Foundayo (orforglipron) [Package insert]*. <https://www.lilly.com>
- Novo Nordisk (2026). *Ozempic tablets (semaglutide) [Package insert]*. <https://www.novo-pi.com/ozempictablets.pdf>
- Lilly direct: <https://www.lilly.com/lillydirect/medicines/foundayo>
- Novo Care: <https://www.novocare.com/pharmacy/ozempic.html> and <https://www.novocare.com/pharmacy/wegovy.html>